Detall de la convocatòria


Objectiu de la convocatòria
IMI brings together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators and offer funding for collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges.
Característiques principals
Topics of the 20th Call:
  • Topic 1: Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in psoriatic arthritis
  • Topic 2: Innovations to accelerate vaccine development and manufacture
  • Topic 3: Academia and industry united innovation and treatment for tuberculosis (UNITE4TB) This topic is part of the IMI AMR Accelerator Programme. Applicants should also read the Questions and Answers on the programme (document last updated November 2019).
  • Topic 4: Tumour plasticity
  • Topic 5: Proton versus photon therapy for oesophageal cancer – a trimodality strategy
  • Topic 6: Handling of protein drug products and stability concerns
  • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
    • Carol Barnwell, Ext.: 1670
    • Marta López, Ext.: 1576
    Convocatòria (URL)
    Informació addicional
    This Call is being run in a two-stage submission and evaluation process.
  • Stage 1 submission deadline: 21 April 2020 (17:00:00 Brussels time)
  • Stage 2 submission deadline: 5 November 2020 (17:00:00 Brussels time)
  • Dotació
    IMI JU collaborative projects are implemented through a co-financing scheme. The IMI JU grants financial support to the eligible entities, while the other entities (including the EFPIA companies) participate in the project with their own resources.
    A causa del COVID-19, aquesta convocatòria ha estat prorrogada fins el 12 de maig.